Q1 Earnings Forecast for LXEO Issued By Leerink Partnrs

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Lexeo Therapeutics in a research report issued to clients and investors on Monday, March 24th. Leerink Partnrs analyst M. Foroohar expects that the company will post earnings of ($0.80) per share for the quarter. The consensus estimate for Lexeo Therapeutics’ current full-year earnings is ($3.14) per share. Leerink Partnrs also issued estimates for Lexeo Therapeutics’ Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.79) EPS and Q4 2025 earnings at ($0.79) EPS.

Several other equities research analysts also recently commented on LXEO. Leerink Partners reduced their price target on shares of Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday. Royal Bank of Canada reduced their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a report on Tuesday. Finally, Chardan Capital reiterated a “buy” rating and set a $25.00 price target on shares of Lexeo Therapeutics in a report on Tuesday. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $22.80.

Lexeo Therapeutics Stock Performance

Shares of LXEO opened at $4.44 on Wednesday. The company has a 50-day moving average of $4.12 and a two-hundred day moving average of $6.67. The stock has a market cap of $146.81 million, a price-to-earnings ratio of -1.41 and a beta of 3.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a one year low of $2.32 and a one year high of $19.50.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09.

Hedge Funds Weigh In On Lexeo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Allostery Investments LP purchased a new stake in shares of Lexeo Therapeutics during the fourth quarter worth $33,000. China Universal Asset Management Co. Ltd. acquired a new position in Lexeo Therapeutics in the 4th quarter worth about $46,000. BNP Paribas Financial Markets raised its stake in shares of Lexeo Therapeutics by 184.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after purchasing an additional 3,591 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at about $69,000. Finally, SG Americas Securities LLC bought a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at approximately $72,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.